For Part 1: Individuals with a diagnosis of advanced or metastatic solid tumor exhausting all available standard of care therapy; Part 2: Individuals with histologically or cytologically confirmed metastatic or locally advanced NSCLC
Have at least 1 injectable tumor
Eastern cooperative oncology group (ECOG) performance status of grade 0 or 1
A participant who can have children must have a negative pregnancy test before the first dose of study treatment and during the study
Thyroid function laboratory values within normal range except for participants on thyroid hormone replacement therapy
You may not be if
Active disease involvement of the CNS (example, primary central nervous system tumors, metastases, leptomeningeal disease). Some exceptions are allowed
Prior history of, or active, significant herpetic infections (example, herpetic keratitis or encephalitis) or active herpetic infections that require ongoing systemic anti-viral therapy
Active infection or condition that requires treatment with systemic anti-infective agents (example, antibiotics, antifungals, or antivirals) within 7 days prior to the first dose of study treatment or chronic use of anti-infective agents
History of solid organ or hematologic stem cell transplantation
Known positive test result for human immunodeficiency virus (HIV) or other immunodeficiency syndrome
History of allergy to protein-based therapies or history of any significant drug allergy (such as anaphylaxis, hepatotoxicity, or immune-mediated thrombocytopenia or anemia)
Clareo Health | A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
